## Modelling exemplification Alessio Crippa

## Aim

The aim of this document is to clarify the modelling assumptions used in the simulations for defining the operational characteristics of ProBio. I first describe the parametric assumptions and use fictitious data for exemplifying the updating evaluation of the trial.

## Modelling assumption

We are going to use Bayesian methods for survival analysis. In a Bayesian framework, a parametric distribution is often selected for modelling a time to event variable, in our case progression free survival (PFS).

A Weibull distribution is typically adopted in many bio-medical contexts, given its flexibility in describing several different shapes and phenomena. A Weibull distribution can be parameterized in terms of a scale  $(\lambda)$  and shape (k) parameter is such a way that it density function assumes the following form:

$$T \sim \text{Weibull}(\lambda, k)$$

$$f(t; \lambda, k) = \lambda k t^{k-1} \exp(-\lambda t^k)$$


The mean in the previous parametrization is  $\lambda^{-\frac{1}{k}} \Gamma(1+\frac{1}{k})$ .

In a Bayesian perspective, we are considering the parameters of interest as random variables rather than fixed values. In particular, we are going to assume a distribution for the scale parameter while fixing the shape parameter at 1.05, as estimated in an international study on similar patients. We adopt a gamma distribution for the scale parameter as it is a conjugate model for the Weibull distribution:

$$\lambda \sim \text{Gamma}(a, b)$$
$$f(\lambda; a, b) = \frac{b^a \lambda^{a-1} \exp(-b\lambda)}{\Gamma(a)}$$

As a priori parameter we are going to use a = 10 and b = 80 as hyperparameters, that corresponds approximately to the information of 10 patient with a mean  $E[\lambda] = \frac{a}{b} = 1/8 = 0.125$ , which then gives a mean PFS time equal to  $E[T] = 0.125^{-1/1.05}\Gamma(1 + \frac{1}{1.05}) = 7.1$ .

Let's compare how the distribution of PFS times changes as the b hyperparameter increases from 80 to 180:



We can compare the distributions by comparing the respective means.

b mean gamma mean time [1,] 80 0.12500000 7.106618 [2,] 100 0.10000000 8.789380 [3,] 120 0.08333333 10.456082 [4,] 140 0.07142857 12.109545 [5,] 160 0.06250000 13.751758 [6,] 180 0.05555556 15.384200

In addition, we might compare how much is the evidence that the distributions differ from each other. For example, what is the probability that then mean time of a Weibull distribution where the  $\lambda$  parameter has a gamma distribution with a = 10 and b = 140 is greater than the mean of a similar distribution but with b = 80? This can be computed using Monte Carlo simulations

|      | b   | mean  | gamma  | mean  | time  | prob | of | superiority |
|------|-----|-------|--------|-------|-------|------|----|-------------|
| [1,] | 80  | 0.125 | 500000 | 7.10  | 06618 |      |    | 0.459       |
| [2,] | 100 | 0.100 | 000000 | 8.78  | 39380 |      |    | 0.659       |
| [3,] | 120 | 0.083 | 333333 | 10.45 | 56082 |      |    | 0.794       |
| [4,] | 140 | 0.071 | 142857 | 12.10 | )9545 |      |    | 0.863       |
| [5,] | 160 | 0.062 | 250000 | 13.75 | 51758 |      |    | 0.927       |
| [6,] | 180 | 0.055 | 555556 | 15.38 | 34200 |      |    | 0.954       |

## Exemplification clinical trial

Let's use a fictitious example data set to exemplify how the hyperparameters are update throughout the trial, how we can decide to ealier stop the trial.

We consider one active treatment being compared vs a control group. Each group consists of 25 patients whose PFS time has been recorded in the first 20 months. The PFS times for those men still alive at the end of the follow-up are marked with a "+" in the table below

| Control   | Treatment   |
|---|---|
| 2.55, 6.43, 2.87, 6.68, 11.91, 6.95, 3.08, 7.43, 10.29, | 8.49, 20.00+, 3.18, 19.61, 20.00+, 15.35, 17.06,        |
| 6.34, 7.99, 19.93, 1.15, 20.00+, 7.43, 5.49, 8.69,      | 20.00+, 10.51, 3.89, 20.00+, 8.12, 6.09, 20.00+,        |
| 0.93, 2.63, 10.88, 16.88, 5.81, 1.42, 3.97, 20.00 +     | 2.66, 8.46, 0.48, 4.81, 5.26, 6.78, 5.62, 1.19, 20.00+, |
|   | 0.31, 5.23  |

The hyperparameters of the Gamma distibution are updated monthly. In particula the hyperparameter a is updated with the number of progressions while b with the amount of time the patients stayed in the trial. For example, in the firs month there have been 1 and 2 progressions in the control and treatment groups. After the first month a = 10 + 1 in the control group, while a = 10 + 2 in the treatment group. Similarly, the observed person times (elevated to the power of 1.05) in the first month were 24.93 and 23.8, so that b = 80 + 24.93 and b = 80 + 23.76 in the control and treatment group. Given the hyperparameters it is possible to compare if the treatment is superior to control group.

The same steps can be repeated monthly:

|                        | Control |       |   |        |        |         | Treatment |       |   |        |        |         |       |
|------------------------|---------|-------|---|--------|--------|---------|-----------|-------|---|--------|--------|---------|-------|
| $\operatorname{month}$ | a       | b     | d | PT     | mu gam | mu time | a         | b     | d | PT     | mu gam | mu time | р     |
| 0                      | 10      | 80.0  | 1 | 24.925 | 0.1250 | 7.107   | 10        | 80.0  | 2 | 23.763 | 0.1250 | 7.107   | 0.499 |
| 1                      | 11      | 104.9 | 2 | 22.534 | 0.1048 | 8.403   | 12        | 103.8 | 1 | 22.171 | 0.1156 | 7.653   | 0.399 |
| 2                      | 13      | 129.1 | 3 | 21.011 | 0.1007 | 8.730   | 13        | 127.5 | 1 | 21.642 | 0.1020 | 8.629   | 0.488 |
| 3                      | 16      | 152.2 | 2 | 18.041 | 0.1051 | 8.381   | 14        | 151.3 | 2 | 20.051 | 0.0925 | 9.464   | 0.602 |
| 4                      | 18      | 172.4 | 0 | 17.000 | 0.1044 | 8.434   | 16        | 173.7 | 1 | 18.806 | 0.0921 | 9.507   | 0.627 |
| 5                      | 18      | 191.6 | 2 | 16.275 | 0.0939 | 9.329   | 17        | 195.0 | 3 | 16.061 | 0.0872 | 10.018  | 0.584 |
| 6                      | 20      | 210.3 | 4 | 13.346 | 0.0951 | 9.218   | 20        | 213.4 | 2 | 13.854 | 0.0937 | 9.351   | 0.523 |
| 7                      | 24      | 225.7 | 3 | 9.810  | 0.1063 | 8.290   | 22        | 229.4 | 0 | 13.000 | 0.0959 | 9.148   | 0.674 |
| 8                      | 27      | 237.1 | 1 | 7.674  | 0.1139 | 7.767   | 22        | 244.5 | 3 | 11.027 | 0.0900 | 9.721   | 0.792 |
| 9                      | 28      | 246.1 | 0 | 7.000  | 0.1138 | 7.773   | 25        | 257.5 | 0 | 10.000 | 0.0971 | 9.040   | 0.720 |
| 10                     | 28      | 254.3 | 2 | 6.149  | 0.1101 | 8.020   | 25        | 269.2 | 1 | 9.489  | 0.0929 | 9.432   | 0.755 |
| 11                     | 30      | 261.6 | 1 | 4.905  | 0.1147 | 7.715   | 26        | 280.5 | 0 | 9.000  | 0.0927 | 9.447   | 0.785 |
| 12                     | 31      | 267.4 | 0 | 4.000  | 0.1159 | 7.636   | 26        | 291.1 | 0 | 9.000  | 0.0893 | 9.789   | 0.845 |
| 13                     | 31      | 272.2 | 0 | 4.000  | 0.1139 | 7.766   | 26        | 301.9 | 0 | 9.000  | 0.0861 | 10.132  | 0.843 |
| 14                     | 31      | 277.0 | 0 | 4.000  | 0.1119 | 7.896   | 26        | 312.6 | 0 | 9.000  | 0.0832 | 10.476  | 0.871 |
| 15                     | 31      | 281.8 | 0 | 4.000  | 0.1100 | 8.026   | 26        | 323.4 | 1 | 8.335  | 0.0804 | 10.820  | 0.879 |
| 16                     | 31      | 286.6 | 1 | 3.877  | 0.1082 | 8.157   | 27        | 333.5 | 0 | 8.000  | 0.0810 | 10.747  | 0.858 |
| 17                     | 32      | 291.3 | 0 | 3.000  | 0.1099 | 8.037   | 27        | 343.1 | 1 | 7.053  | 0.0787 | 11.043  | 0.897 |
| 18                     | 32      | 294.9 | 0 | 3.000  | 0.1085 | 8.133   | 28        | 351.7 | 0 | 7.000  | 0.0796 | 10.921  | 0.882 |
| 19                     | 32      | 298.6 | 1 | 2.931  | 0.1072 | 8.228   | 28        | 360.2 | 1 | 6.592  | 0.0777 | 11.172  | 0.884 |
| 20                     | 33      | 302.2 | 0 | 0.000  | 0.1092 | 8.082   | 29        | 368.2 | 0 | 0.000  | 0.0788 | 11.035  | 0.920 |

